ICHR

Ichor Holdings

$33.65

-5.80%
Nov 16, 2026
Bobby Quantitative Model
Ichor Holdings is a designer, engineer, and manufacturer of critical fluid delivery subsystems and precision-machined components used primarily in semiconductor capital equipment, with additional exposure to defense/aerospace and medical end markets; its gas and chemical delivery systems enable the precise control of specialized gases and reactive chemistries in etch, electroplating, and cleaning processes, and the company derives the majority of revenue from Singapore-based operations. Ichor occupies a niche but strategically embedded position in the semiconductor supply chain as a key outsourced subsystem partner to the major OEMs (Applied Materials, Lam Research, and others), making it a high-beta derivative play on wafer fab equipment spending rather than a chipmaker itself. The current investor narrative is dominated by a violent boom-bust cycle: a sharp 2026 revenue acceleration (Q3 revenue up 37.4% year-over-year to $328.7 million) and a swing back to profitability have collided with a brutal ~50% three-month drawdown as the stock gave back most of a spectacular run, leaving investors debating whether the pullback is a buying opportunity in an early-cycle recovery or a warning that the WFE upcycle is peaking. A recent $196.8 million equity raise that bolstered the balance sheet to $213.5 million in cash, alongside persistent negative free cash flow from working-capital build, frames the central tension between growth investment and cash discipline.

People also watch

Nvidia

Nvidia

NVDA

Analysis
TSMC

TSMC

TSM

Analysis
Broadcom

Broadcom

AVGO

Analysis
Micron Technology

Micron Technology

MU

Analysis
AMD

AMD

AMD

Analysis

BobbyInvestment Opinion: Should I buy ICHR Today?

Rating: Speculative Buy (accumulate with tight risk controls). The core thesis is that ICHR is an early-cycle WFE recovery trading at roughly 7x the consensus forward EPS of $5.10 ($35.72 / $5.10), a multiple that prices in severe skepticism about the durability of the upcycle even as Q3 revenue grew 37.36% YoY to $328.70 million and net income swung to $20.95 million from a -$22.85 million loss a year earlier. The Buy ratings maintained by B. Riley (reiterated November 9, 2026), TD Cowen, Stifel, and Needham through a -49.73% three-month decline, with no Sell ratings in the recent record, support treating the selloff as a valuation reset rather than a fundamental break — though with only 2 analysts in the estimate set and no explicit price targets in the data, the consensus cannot be used to compute a precise upside figure.

Supporting evidence is unusually strong for a stock at 25.9% of its 52-week range: revenue accelerated for three consecutive quarters ($256.07M Q1 → $294.78M Q2 → $328.70M Q3), gross margin expanded from 11.63% to 13.90% to 15.83%, and operating margin turned positive at 6.94% versus -8.12% a year ago — textbook cyclical operating leverage. Valuation sits at the very bottom of history, with PS of 0.68x versus a 2.46x-11.29x historical band and P/B of 0.98x versus a 0.87x-3.84x range, while the balance sheet was fortified by a $196.8 million equity raise that lifted cash to $213.50 million and supports a 3.16 current ratio and 0.24 debt-to-equity. The offsetting data point is cash: trailing free cash flow is -$67.24 million and Q3 operating cash flow was -$28.83 million on a -$58.84 million working-capital build, so the recovery is not yet self-funding.

The biggest risks that could invalidate the thesis are (1) the forward $5.10 EPS estimate failing to materialize — if the working-capital-heavy ramp stalls and estimates are cut, the sub-1x PS becomes a value trap rather than a bargain; (2) continued negative free cash flow forcing further dilution or drawing down the $213.50 million cash buffer; and (3) a WFE digestion phase hitting revenue and margins simultaneously given Ichor's role as a high-beta derivative play on OEM capex at Applied Materials and Lam Research. This rating would upgrade to a full Buy if free cash flow inflects positive and gross margin pushes toward the 17.9% prior-cycle peak, and would downgrade to Sell on a decisive break below the $28.03 52-week low or evidence of forward estimate cuts. Verdict: undervalued relative to its own history and to semicap peers on a forward-earnings basis, but fairly-to-fully priced on trailing fundamentals — the discount is real but conditional on execution.

Sign up to view all

ICHR 12-Month Price Forecast

The setup is a classic early-cycle recovery priced as if the cycle has already peaked: 37.36% YoY revenue growth and a swing to $20.95 million net income against a stock at 25.9% of its 52-week range and roughly 7x the $5.10 forward EPS. The bull case is supported by genuine operating leverage — gross margin up 420 basis points across three quarters — and a balance sheet fortified by the $196.8 million raise to $213.50 million in cash with 0.24 debt-to-equity. The bear case is equally concrete: -$67.24 million trailing free cash flow, a -$58.84 million working-capital build, and a -75.04% max drawdown that shows how violently sentiment can reverse. Confidence is medium rather than high because only 2 analysts contribute estimates, no explicit price targets are available, and the entire thesis hinges on a forward EPS figure the market is visibly discounting. I would upgrade to high confidence on a positive free-cash-flow quarter or gross margin above 17%, and downgrade to neutral on a break below $28.03 or any cut to the $4.95 low-end EPS estimate.

Historical Price
Current Price $33.65
Average Target $33.65
High Target $38.70
Low Target $28.60

Wall Street consensus

Coverage is thin, with only 2 analysts providing estimates, but the institutional ratings feed shows a broader roster of firms (B. Riley, TD Cowen, Stifel, Needham, Oppenheimer) that have maintained Buy ratings through the selloff — notably, B. Riley reiterated Buy on November 9, 2026, and TD Cowen, Stifel, and Needham all reaffirmed Buy on November 3 following Q3 results, while Oppenheimer remained at Perform. The consensus leans bullish with no Sell ratings in the recent record, and the average forward EPS estimate of $5.10 (range $4.95-$5.26) and average revenue estimate of $2.20 billion (range $2.15-$2.25 billion) imply analysts expect a full-year earnings recovery that, at the current $35.72 price, would value the stock at roughly 7x forward EPS — a striking disconnect from the price action.\n\nThe estimate range is relatively tight (EPS $4.95-$5.26, revenue $2.15-$2.25 billion), signaling reasonable conviction among the small covering group about the magnitude of the recovery, though the absence of explicit price targets in the provided data prevents calculation of a precise consensus upside. The high-end estimates assume the WFE upcycle accelerates and Ichor's operating leverage drives margins toward prior-cycle peaks, while the low end likely prices in a slower ramp or margin compression from the working-capital-heavy growth. The key signal is the persistence of Buy ratings through a -50% drawdown — analysts are treating the selloff as a valuation opportunity rather than a fundamental deterioration — but with only 2 analysts in the estimate set and no price targets available, price discovery remains inefficient and the stock is prone to the extreme volatility already demonstrated by its -75% max drawdown.

Drowning in data?

Find the real signal!

Bulls vs Bears: ICHR Investment Factors

The bear case currently has stronger near-term evidence: a -75.04% max drawdown, -49.73% three-month decline, -$67.24 million trailing free cash flow, and a stock sitting at just 25.9% of its 52-week range all confirm that momentum and cash discipline have broken down, and the market is explicitly questioning whether the WFE upcycle is peaking. The bull case rests on genuinely impressive fundamentals — 37.36% YoY revenue growth, a swing to $20.95 million net income, gross margin expansion from 11.63% to 15.83% across three quarters, and a 0.68x PS at the bottom of a 2.46x-11.29x historical band — plus persistent Buy ratings from B. Riley, TD Cowen, Stifel, and Needham through the selloff. The single most important tension is whether the forward $5.10 EPS estimate is real: at 7x forward earnings the stock is extraordinarily cheap if the recovery holds, but if the working-capital-heavy ramp stalls and estimates are cut, the sub-1x PS is a value trap rather than a bargain. Resolution likely comes from the next one or two quarters of revenue cadence and free-cash-flow inflection, not from further multiple expansion.

Bullish

  • Revenue inflecting at 37% YoY: Q3 2026 revenue of $328.7 million grew 37.36% year-over-year versus $239.3 million in Q3 2025, and rose sequentially from $256.1 million in Q1 to $294.8 million in Q2 to $328.7 million in Q3 — three consecutive quarters of acceleration after four flat-to-declining quarters. The sequential cadence of roughly +15% then +11.5% suggests demand from semiconductor OEMs is genuinely strengthening rather than a one-quarter blip.
  • Operating leverage swinging to profit: Net income flipped to $20.95 million (6.37% net margin, EPS $0.56) in Q3 2026 from a -$22.85 million loss (-9.55% margin) a year earlier, while gross margin expanded from 11.63% in Q1 to 13.90% in Q2 to 15.83% in Q3 and operating margin turned positive at 6.94% versus -8.12% a year ago. This is textbook cyclical operating leverage — incremental revenue is dropping through to profit at a steep rate.
  • Deep valuation discount to history: At $35.72 the stock trades at a PS of 0.68x and price-to-book of 0.98x, versus a historical PS band of roughly 2.46x to 11.29x and a P/B range of 0.87x-3.84x — the current multiple sits at the very bottom of its multi-year range, below even the 2023-2024 downturn. The consensus forward EPS of $5.10 implies roughly 7x forward earnings, an extraordinarily low multiple if the recovery holds.
  • Analysts hold Buy through the selloff: Despite a -49.73% three-month decline, B. Riley reiterated Buy on November 9, 2026, and TD Cowen, Stifel, and Needham all reaffirmed Buy on November 3 following Q3 results, with no Sell ratings in the recent record. The forward EPS estimate range of $4.95-$5.26 and revenue range of $2.15-$2.25 billion are tight, signaling reasonable conviction in the magnitude of the recovery among the small covering group.

Bearish

  • Falling knife: -75% max drawdown: The stock has collapsed from a cycle peak of $112.28 on June 30, 2026 to $35.72, a -75.04% max drawdown, and now sits at just 25.9% of its 52-week range (low $28.03, high $105.46). The 1-month change of -25.37% and 3-month change of -49.73% show momentum has decisively broken, and the -23.11% one-month relative strength versus a SPY that fell only -2.26% signals severe idiosyncratic selling pressure.
  • Negative free cash flow and cash burn: Trailing free cash flow is -$67.24 million, Q3 operating cash flow was -$28.83 million, and the cash-flow-to-debt ratio is -0.19 — the business is consuming rather than generating cash precisely as it ramps. The -$58.84 million working-capital build (inventory -$39.54 million, receivables -$35.96 million) means growth is being financed by the balance sheet, and ROE remains negative at -7.95% on a trailing basis.
  • Thin margins below prior peaks: Even at Q3's improved 15.83% gross margin, Ichor remains well below its prior-cycle peak of 17.9% in Q3 2022, and the trailing gross margin of 9.26% with a -5.57% net margin is structurally inferior to fab-equipment OEMs. As a subsystem supplier to Applied Materials and Lam Research, Ichor lacks the pricing power to defend margins if input costs rise or OEMs push cost reductions down the supply chain.
  • Valuation could be a value trap: The sub-1x PS and 0.98x P/B sit at historical lows not seen even in the 2023-2024 downturn, which either signals a compelling opportunity or that the market expects earnings estimates to be revised sharply lower. With trailing EPS of -$0.08, a trailing PE of -12.31x, and a negative EV/EBITDA of -95.50x, the entire bull case rests on the forward $5.10 EPS estimate materializing — a binary outcome the market is clearly discounting.

ICHR Technical Analysis

The prevailing trend is a violent boom-bust reversal: despite a still-positive 1-year price change of +140.05%, the stock has collapsed from its cycle peak, with the current price of $35.72 sitting at just 25.9% of its 52-week range (low of $28.03, high of $105.46). That positioning near the bottom of the annual range, combined with a staggering -75.04% max drawdown from the highs, signals a falling-knife dynamic rather than a healthy pullback — momentum has decisively broken, and the stock is now testing territory that previously marked the cycle trough. The +75.01% YTD gain is a vestige of the first-half melt-up and masks the severity of the second-half collapse.\n\nShort-term momentum is unambiguously negative and accelerating to the downside: the 1-month change of -25.37% and 3-month change of -49.73% show a relentless cascade, with the 6-month change of -51.25% confirming that essentially all of the year's gains have been erased since mid-summer. The divergence between the +140% 1-year return and the -50% 3-month return is a textbook trend-reversal signal — the long-term uptrend has been invalidated, and the 1-month relative strength of -23.11% versus SPY (which fell only -2.26%) underscores severe idiosyncratic selling pressure. The most recent sessions show a modest bounce from the $28.03 low to $35.72, but with volume data unavailable (reported as 0), conviction behind the rebound cannot be confirmed.\n\nKey technical levels are well defined: support rests at the 52-week low of $28.03, and a breakdown below that level would signal capitulation and open the door to new lows, while resistance sits at the $105.46 high — a distant 195% above current levels — with intermediate overhead supply likely clustered around the $50-$60 breakdown zone. The stock's extreme volatility is evident in the -75.04% max drawdown and the 140% one-year gain, implying a beta well above market; while an explicit beta figure is not available in the provided data, the magnitude of these swings relative to SPY's +12.27% 1-year return argues for materially reduced position sizing and tight risk controls. A sustained reclaim of the $50 area would be the first meaningful sign of stabilization; failure at $28 would confirm the downtrend's continuation.

Beta

—

—

Max Drawdown

-75.0%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+129.8%

Cumulative gain past year

PeriodICHR ReturnS&P 500
1m-20.1%-3.0%
3m-49.1%-3.6%
6m-48.8%-0.2%
1y+129.8%+10.1%
ytd+64.9%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ICHR Fundamental Analysis

The revenue trajectory has inflected sharply upward: Q3 2026 revenue of $328.70 million grew 37.36% year-over-year versus Q3 2025's $239.30 million, and rose sequentially from $294.78 million in Q2 and $256.07 million in Q1, marking three consecutive quarters of acceleration. This is a genuine cyclical recovery — the prior four quarters (Q4 2024 through Q3 2025) were flat-to-declining around $223-$244 million — and the sequential cadence (+15% Q1-to-Q2, +11.5% Q2-to-Q3) suggests demand from semiconductor OEMs is strengthening. The growth trend supports the bull case that Ichor is early in a WFE upcycle, though the stock's collapse implies the market now questions the durability of that trajectory.\n\nProfitability has swung decisively positive after a string of losses: Q3 2026 net income reached $20.95 million (6.37% net margin) and EPS of $0.56, a dramatic reversal from the -$22.85 million loss (-9.55% margin) in Q3 2025 and the -$15.96 million loss in Q4 2025. Gross margin expanded to 15.83% in Q3 from 13.90% in Q2 and 11.63% in Q1, while operating margin turned positive at 6.94% versus -8.12% a year ago — clear evidence of operating leverage as volumes recover. Still, the 15.83% gross margin remains thin for a semiconductor-equipment supplier and below the company's prior-cycle peaks (17.9% in Q3 2022), indicating pricing and mix have not fully normalized.\n\nThe balance sheet is a mixed picture: liquidity is strong with a current ratio of 3.16 and $213.50 million in cash (up from $89.09 million after the Q2 equity raise), and leverage is modest at a debt-to-equity of 0.24, but cash generation is the weak link — trailing free cash flow is -$67.24 million, with Q3 operating cash flow of -$28.83 million driven by a -$58.84 million working-capital build (inventory -$39.54 million, receivables -$35.96 million) as the company funds its growth. ROE remains negative at -7.95% on a trailing basis, and the cash-flow-to-debt ratio of -0.19 highlights that the business is currently consuming rather than generating cash, making the recent equity infusion critical to funding the ramp.

Quarterly Revenue

$328699000.0B

2026-09

Revenue YoY Growth

+37.4%

YoY Comparison

Gross Margin

15.8%

Latest Quarter

Free Cash Flow

$-67238000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ICHR Overvalued?

Because trailing net income is negative (EPS of -$0.08, trailing PE of -12.31x), the PE ratio is not a meaningful primary metric; instead, the price-to-sales ratio of 0.68x is the appropriate anchor, and it is strikingly low for a company growing revenue 37% year-over-year. The forward PE of -0.09x and negative EV/EBITDA of -95.50x reflect trailing losses and are not informative, but the analyst consensus EPS estimate of $5.10 for the forward period implies the market expects a dramatic earnings recovery — at $35.72, that forward estimate equates to roughly 7x forward earnings, an extraordinarily cheap multiple if achievable. The enormous gap between the negative trailing multiple and the positive forward estimate captures the market's binary debate over whether the recovery is real.\n\nAgainst semiconductor-industry norms, Ichor trades at a deep discount: its PS of 0.68x and price-to-book of 0.98x are far below the multiples typically commanded by semiconductor-equipment peers (often 3-6x sales), and even its own historical PS band (which ranged from 2.46x to 11.29x over the past several quarters) shows the current level is an outlier to the downside. The discount is partly justified by the thin 9.26% gross margin and -5.57% net margin, which are structurally inferior to fab-equipment OEMs, but a sub-1x PS on a business inflecting to profitability suggests the market is pricing significant skepticism about the durability of the upcycle.\n\nHistorically, Ichor's PS ratio has ranged from roughly 2.5x (Q3 2025) to 11.3x (Q2 2026), and the current 0.68x sits at the very bottom of that band — a level not seen even during the 2023-2024 downturn. Similarly, the price-to-book of 0.98x is near the low end of its multi-year range (0.87x-3.84x). This positioning at historical valuation lows, combined with the improving fundamentals, suggests either a compelling value opportunity or a market signal that earnings estimates are about to be revised sharply lower — the resolution of that tension will define the stock's next move.

PE

-12.3x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 6x~30x

vs. Industry Avg

54.4x

Industry PE ~54.4x*

EV/EBITDA

-95.5x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on cash consumption during the ramp. Trailing free cash flow is -$67.24 million, Q3 operating cash flow was -$28.83 million, and the cash-flow-to-debt ratio of -0.19 shows the business is burning cash even as revenue grows 37.36% year-over-year, driven by a -$58.84 million working-capital build (inventory -$39.54 million, receivables -$35.96 million). The $196.8 million equity raise lifted cash to $213.5 million and kept debt-to-equity at a modest 0.24 with a 3.16 current ratio, but continued negative free cash flow would force further dilution or draw down that buffer. Margin risk is also material: the 15.83% Q3 gross margin remains below the 17.9% prior-cycle peak, and trailing gross margin of 9.26% with a -5.57% net margin leaves little cushion if OEM pricing pressure intensifies. Finally, revenue is concentrated in semiconductor capital equipment and geographically in Singapore, so a single demand or logistics shock hits the whole model.

Market and competitive risks are dominated by valuation compression and cyclicality. The stock has already suffered a -75.04% max drawdown and a -49.73% three-month decline, with one-month relative strength of -23.11% versus SPY's -2.26%, demonstrating that sentiment can reverse violently regardless of fundamentals. Ichor is a high-beta derivative play on wafer fab equipment spending rather than a chipmaker, so its fate is tied to capex budgets at Applied Materials, Lam Research, and other OEMs — a WFE digestion phase would hit revenue and margins simultaneously. The sub-1x PS and 0.98x P/B reflect the market pricing skepticism about upcycle durability; if peers re-rate lower or the sector rotates out of semicap, Ichor's discount could widen further. Thin analyst coverage (2 estimates, no explicit price targets) amplifies volatility because price discovery is inefficient and large holders can move the stock on limited news.

In a worst-case scenario, the WFE upcycle stalls in the next two quarters, Q4 revenue fails to build on the $328.7 million Q3 level, working-capital build continues, and the forward $5.10 EPS estimate is cut sharply — triggering downgrades from the Buy-rated firms and a retest of the 52-week low of $28.03, which is roughly -21.5% from the current $35.72. A capitulation break below $28.03 would open the door to new lows and, extrapolating the -75.04% max drawdown already realized, a further -30% to -40% from current levels is plausible in a full cyclical reversal. The realistic downside band is therefore -21.5% to the 52-week low, extending toward -40% if the trough fails to hold.

FAQ

Ranked by severity: first, cash-flow risk — trailing free cash flow is -$67.24 million and Q3 operating cash flow was -$28.83 million on a -$58.84 million working-capital build, so the recovery is not self-funding and continued burn would pressure the $213.50 million cash balance or force further dilution after the $196.8 million raise. Second, estimate risk — the entire bull case rests on the $5.10 forward EPS (range $4.95-$5.26); a cut would collapse the 7x forward multiple thesis and likely trigger downgrades from the currently Buy-rated firms. Third, cyclical and competitive risk — Ichor is a subsystem supplier to Applied Materials and Lam Research with a 15.83% gross margin still below its 17.9% prior-cycle peak, leaving little pricing power if OEMs push cost reductions down the supply chain or WFE spending digests. Fourth, market-structure risk — the -75.04% max drawdown, -25.37% one-month decline, and -23.11% one-month relative strength versus SPY show how violently sentiment can move a thinly covered, high-beta name.

The scenario framework assigns a 50% probability to the base case of $42-$55, a 25% probability to the bull case of $65-$80, and a 25% probability to the bear case of $20-$28. The base case is most likely: it assumes forward EPS of $5.10 is broadly achieved, full-year revenue lands near the $2.20 billion consensus, gross margin holds at or above 15.83%, and free cash flow approaches breakeven — enough for the stock to stabilize above the $28.03 low and partially retrace its -49.73% three-month decline, but not enough for a full re-rating. The bull case requires the WFE upcycle to accelerate into 2027 with gross margin pushing toward the 17.9% prior-cycle peak and a re-rating to 13x-16x forward earnings. The bear case assumes the upcycle stalls within one to two quarters, Q4 revenue fails to build on $328.70 million, and the $5.10 estimate is cut, retesting and breaking $28.03. The key assumption across all three is the durability of the forward EPS estimate.

On the metrics that matter for a cyclical recovery, ICHR screens deeply undervalued relative to its own history. The PS ratio of 0.68x sits at the very bottom of a multi-year band of roughly 2.46x-11.29x, and price-to-book of 0.98x is near the low end of a 0.87x-3.84x range — levels not seen even in the 2023-2024 downturn. Trailing PE of -12.31x and EV/EBITDA of -95.50x are not meaningful because trailing EPS is -$0.08, so the forward lens is the right one: $35.72 divided by the $5.10 consensus forward EPS implies about 7x forward earnings. The market is therefore pricing significant skepticism that the recovery is durable — essentially treating the current earnings run-rate as a cyclical peak rather than an early-cycle inflection. If the forward estimate holds, the stock is undervalued; if estimates are cut, the discount is a value trap. That binary is the entire valuation debate.

From a risk/reward standpoint, ICHR offers an asymmetric setup but with unusually wide error bars. The reward: at $35.72 the stock trades at roughly 7x the consensus forward EPS of $5.10 and 0.68x sales, while revenue grew 37.36% year-over-year and net income swung to $20.95 million from a -$22.85 million loss — if the recovery holds, a re-rating to even 13x-16x forward earnings implies $65-$80. The risk: trailing free cash flow is -$67.24 million, the stock has already fallen -49.73% in three months and sits just 25.9% of its 52-week range, and a break below the $28.03 low would imply roughly -21.5% downside with further capitulation possible. With only 2 analysts in the estimate set and no explicit price targets, there is no consensus upside figure to anchor on. It is a reasonable buy only for investors with high risk tolerance, a multi-quarter horizon, and position sizes small enough to absorb another -30% to -40% move; it is not suitable for conservative or income-oriented portfolios.

ICHR is best suited to a medium-term cyclical recovery holding period of at least 12-18 months, not short-term trading. The evidence: the stock is in a confirmed downtrend with a -75.04% max drawdown, -49.73% three-month decline, and -25.37% one-month decline, so near-term price action is driven by momentum and sentiment rather than fundamentals — a poor setup for short-term longs. The 1-year return of +140.05% versus SPY's +12.27% implies a beta well above market, meaning daily volatility is high and stop-loss discipline is essential. There is no dividend (payout ratio of 0), so there is no income cushion while waiting. Earnings visibility is limited by thin coverage (2 analysts, no explicit price targets) and the binary forward EPS debate. A concrete minimum holding period of 12-18 months allows time for the working-capital build to unwind, free cash flow to inflect, and the next one to two quarters of revenue cadence to validate or refute the recovery thesis.